Reasonability of MR formulations [Bioanalytics]

posted by Helmut Homepage – Vienna, Austria, 2009-07-06 20:51 (6202 d 15:36 ago) – Posting: # 3934
Views: 3,603

Dear Daniel!

❝ [...] Due this long half life a modified release formulation is not necessary.


Exactly. But not everything in the world of big pharma is driven by science. :angry: I once came across a drug, where the innovator got his first market authorization with a modified release formulation despite a half-live of two days. Obviously this was just done to make the life of generic companies miserable (it’s much more difficult to demonstrate BE of an MR formulation).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
301 visitors (0 registered, 301 guests [including 17 identified bots]).
Forum time: 12:27 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5